Mara Epstein to Aged
This is a "connection" page, showing publications Mara Epstein has written about Aged.
Connection Strength
0.964
-
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer. 2023 06 15; 152(12):2485-2492.
Score: 0.071
-
Epstein MM, Sundaresan D, Fair M, Fouayzi H, Warner ET, Garber LD, Gurwitz JH, Field TS. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts. Cancer Causes Control. 2022 Oct; 33(10):1313-1323.
Score: 0.068
-
Casta?eda-Avila MA, Lapane KL, Person SD, Zhou Y, Gurwitz J, Mazor KM, Epstein MM. Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematol Oncol. 2022 Aug; 40(3):409-416.
Score: 0.066
-
Casta?eda-Avila MA, Jesdale BM, Beccia A, Bey GS, Epstein MM. Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity. Cancer Causes Control. 2021 Sep; 32(9):1021-1028.
Score: 0.063
-
Castaneda-Avila MA, Ulbricht CM, Epstein MM. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. Ann Hematol. 2021 Apr; 100(4):855-863.
Score: 0.061
-
Casta?eda-Avila MA, Lapane KL, Jesdale BM, Crawford SL, Epstein MM. Variation in Colorectal Cancer Screening Practices According to Cardiovascular Disease Status and Race/Ethnicity. J Racial Ethn Health Disparities. 2021 02; 8(1):166-173.
Score: 0.058
-
Epstein MM, Saphirak C, Zhou Y, LeBlanc C, Rosmarin AG, Ash A, Singh S, Fisher K, Birmann BM, Gurwitz JH. Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf. 2020 01; 29(1):69-76.
Score: 0.056
-
Epstein MM, Rosner B, Breen EC, Batista JL, Giovannucci EL, Magpantay L, Aster JC, Rodig SJ, Bertrand KA, Laden F, Mart?nez-Maza O, Birmann BM. Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies. Haematologica. 2018 10; 103(10):1679-1687.
Score: 0.051
-
Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Ulcickas Yood M, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
Score: 0.047
-
Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012 Sep 05; 104(17):1335-42.
Score: 0.034
-
Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, Wolk A, H?kansson N, Fall K, Andersson SO, Andr?n O. Dietary fatty acid intake and prostate cancer survival in ?rebro County, Sweden. Am J Epidemiol. 2012 Aug 01; 176(3):240-52.
Score: 0.034
-
Epstein MM, Kasperzyk JL, Andr?n O, Giovannucci EL, Wolk A, H?kansson N, Andersson SO, Johansson JE, Fall K, Mucci LA. Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr. 2011 Mar; 93(3):586-93.
Score: 0.030
-
Fisher KA, Epstein MM, Nguyen N, Fouayzi H, Crawford S, Linas BP, Mazor KM. COVID-19 clinical trials: who is likely to participate and why? J Comp Eff Res. 2024 08; 13(8):e230181.
Score: 0.019
-
Fisher KA, Mazor KM, Epstein MM, Goldthwait L, Abu Ghazaleh H, Zhou Y, Crawford S, Marathe J, Linas BP. Long COVID awareness and receipt of medical care: a survey among populations at risk for disparities. Front Public Health. 2024; 12:1360341.
Score: 0.019
-
Casta?eda-Avila MA, Su?rez-Ramos T, Torres-Cintr?n CR, Epstein MM, Gierbolini-Berm?dez A, Tortolero-Luna G, Ortiz-Ortiz KJ. Multiple myeloma incidence, mortality, and survival differences at the intersection of sex, age, and race/ethnicity: A comparison between Puerto Rico and the United States SEER population. Cancer Epidemiol. 2024 Apr; 89:102537.
Score: 0.019
-
Castaneda-Avila MA, Oyinbo AG, Epstein MM, Ortiz-Ortiz KJ, Tortolero-Luna G, Lapane KL. Trends and Factors Associated with Fecal Occult Blood Test Utilization among Hispanic Adults in Puerto Rico and the United States: BRFSS 2012-2020. Cancer Prev Res (Phila). 2023 04 03; 16(4):229-237.
Score: 0.018
-
Fillmore NR, DuMontier C, Yildirim C, La J, Epstein MM, Cheng D, Cirstea D, Yellapragada S, Abel GA, Gaziano JM, Do N, Brophy M, Kim DH, Munshi NC, Driver JA. Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093.
Score: 0.016
-
Ardisson Korat AV, Chiu YH, Bertrand KA, Zhang S, Epstein MM, Rosner BA, Chiuve S, Campos H, Giovannucci EL, Chavarro JE, Birmann BM. Red blood cell membrane trans fatty acid levels and risk of non-Hodgkin lymphoma: a prospective nested case-control study. Am J Clin Nutr. 2020 12 10; 112(6):1576-1583.
Score: 0.015
-
Frendl DM, FitzGerald G, Epstein MM, Allison JJ, Sokoloff MH, Ware JE. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool. PLoS One. 2020; 15(12):e0240039.
Score: 0.015
-
Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
Score: 0.015
-
Frendl DM, Epstein MM, Fouayzi H, Krajenta R, Rybicki BA, Sokoloff MH. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data. Cancer Causes Control. 2020 Sep; 31(9):861-867.
Score: 0.015
-
Meyer MS, Mucci LA, Andersson SO, Andr?n O, Johansson JE, Tretli S, Adami HO. Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol. 2010 Sep; 58(3):427-32.
Score: 0.015
-
Lee C, Check DK, Manace Brenman L, Kushi LH, Epstein MM, Neslund-Dudas C, Pawloski PA, Achacoso N, Laurent C, Fehrenbacher L, Habel LA. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
Score: 0.014
-
Banegas MP, Rivera DR, O'Keeffe-Rosetti MC, Carroll NM, Pawloski PA, Tabano DC, Epstein MM, Yeung K, Hornbrook MC, Lu C, Ritzwoller DP. Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML. J Natl Compr Canc Netw. 2019 10 01; 17(10):1166-1172.
Score: 0.014
-
Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell B, Pearce CL, Spencer Feigelson H. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2019 05; 28(5):996-999.
Score: 0.013
-
Chiu YH, Bertrand KA, Zhang S, Laden F, Epstein MM, Rosner BA, Chiuve S, Campos H, Giovannucci EL, Chavarro JE, Birmann BM. A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma. Int J Cancer. 2018 10 15; 143(8):1914-1922.
Score: 0.013
-
Mack DS, Epstein MM, Dub? C, Clark RE, Lapane KL. Screening mammography among nursing home residents in the United States: Current guidelines and practice. J Geriatr Oncol. 2018 11; 9(6):626-634.
Score: 0.013
-
Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol. 2008 Jun; 9(6):550-8.
Score: 0.013
-
Alford SH, Divine G, Chao C, Habel LA, Janakiraman N, Wang Y, Feigelson HS, Scholes D, Roblin D, Epstein MM, Engel L, Havstad S, Wells K, Yood MU, Fortuny J, Johnson CC. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018 01; 29(1):143-156.
Score: 0.012
-
Downer MK, Batista JL, Mucci LA, Stampfer MJ, Epstein MM, H?kansson N, Wolk A, Johansson JE, Andr?n O, Fall K, Andersson SO. Dairy intake in relation to prostate cancer survival. Int J Cancer. 2017 05 01; 140(9):2060-2069.
Score: 0.012
-
Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA. Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis. 2016 Mar; 37(3):262-8.
Score: 0.011
-
Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, Mucci LA. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol. 2014 Sep 20; 32(27):3033-8.
Score: 0.010
-
Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul; 74(10):1034-42.
Score: 0.010
-
Russnes KM, Wilson KM, Epstein MM, Kasperzyk JL, Stampfer MJ, Kenfield SA, Smeland S, Blomhoff R, Giovannucci EL, Willett WC, Mucci LA. Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-Up Study. Int J Cancer. 2014 Mar 01; 134(5):1156-65.
Score: 0.009
-
Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
Score: 0.009
-
Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E, Mucci LA. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
Score: 0.008